Value-Based Care

FDA clears Roche and Eli Lilly's first blood test to both rule in and rule out amyloid pathology in Alzheimer disease.

The third-gen PCKS9 inhibitor was approved in December 2025 as adjunctive treatment alongside diet and exercise for adults with hypercholesterolemia.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.

Multidisciplinary geriatric oncology helps personalize breast cancer care and preserve quality of life for older adults.

Anosheh Afghahi, MD, explains how integrated health technologies can improve clinical trial matching, efficiency, and equity.

Enrique Soto Perez de Celis, MD, PhD, discusses designing breast cancer trials around outcomes older adults value, including independence and quality of life.

Everyday discrimination was associated with delayed care, greater emergency department use, and lower preventive care use among US adults.

CMS value-based payment models underrepresent Black, Hispanic, dual-eligible, and disadvantaged Medicare beneficiaries compared with the broader population.

Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve enrollment.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

Urs Weber, MD, explains how multidisciplinary teams streamline biomarker testing and improve treatment planning in thoracic oncology.

Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.

Cognitive rehabilitation significantly improved goal attainment and satisfaction in adults with long COVID-related cognitive impairment.

CMS proposes major Medicare reforms to ACOs, physician pay, and MIPS reporting, aiming to reward outcomes over service volume by 2029.

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.

Hospital-at-home meets inpatient safety, PBM insulin settlement lowers costs, SNAP narrows screening gaps, and execs warn innovation outpaces reimbursement.

Health system executives say Medicaid cuts, payer disputes, and misaligned incentives are driving the affordability crisis in 2026.

Stefanie Houseknecht, PharmD, explains how oncology pharmacists support biomarker testing, targeted therapy selection, and patient education in lung cancer care.